Ensysce Biosciences, Inc. (ENSC) — Institutional Holders, Q2 2026
18 institutional investment managers reported a ENSC position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $246.1K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
ENSC in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- JANE STREET GROUPAdded · +195,263 sh+$56.6K
- Virtu FinancialAdded · +82,078 sh+$23.8K
- XTX Topco LtdAdded · +52,642 sh+$15.3K
- SUSQUEHANNA INTERNATIONAL GROUP, LLPNew · +34,280 sh+$9.9K
- CITADEL ADVISORSAdded · +28,830 sh+$8.4K
Biggest sellers
- VANGUARD FIDUCIARYSold out · -23,854 sh-$6.9K
- GEODE CAPITAL MANAGEMENTTrimmed · -11,692 sh-$3.4K
- UBS Group AGSold out · -8,791 sh-$2.5K
ENSC 13F holders ranked 1–18 of 18
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | JANE STREET GROUP#1 · 208,833 sh | 208,833 | $60.6K | 0.00% | +1438.9% |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C.#2 · 149,711 sh | 149,711 | $43.4K | <0.01% | 0.0% |
| 3 | Virtu Financial#3 · 95,391 sh | 95,391 | $28.0K | <0.01% | +616.5% |
| 4 | PERCEPTIVE ADVISORS#4 · 86,666 sh | 86,666 | $25.1K | <0.01% | 0.0% |
| 5 | CITADEL ADVISORS#5 · 86,193 sh | 86,193 | $25.0K | 0.00% | +50.3% |
| 6 | XTX Topco Ltd#6 · 77,005 sh | 77,005 | $22.3K | <0.01% | +216.1% |
| 7 | GEODE CAPITAL MANAGEMENT#7 · 62,188 sh | 62,188 | $18.0K | 0.00% | -15.8% |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP#8 · 34,280 sh | 34,280 | $9.9K | 0.00% | New |
| 9 | TRU INDEPENDENCE ASSET MANAGEMENT 2#9 · 13,000 sh | 13,000 | $3.8K | <0.01% | 0.0% |
| 10 | TWO SIGMA SECURITIES#10 · 12,953 sh | 12,953 | $3.8K | <0.01% | New |
| 11 | VANGUARD CAPITAL MANAGEMENT#11 · 12,854 sh | 12,854 | $3.7K | 0.00% | 0.0% |
| 12 | Tower Research Capital (TRC)#12 · 6,094 sh | 6,094 | $1.8K | 0.00% | 0.0% |
| 13 | BARCLAYS PLC#13 · 1,440 sh | 1,440 | $418.00 | 0.00% | New |
| 14 | SBI Securities , Ltd.#14 · 641 sh | 641 | $186.00 | — | +31.9% |
| 15 | BlackRock#15 · 65 sh | 65 | $19.00 | 0.00% | 0.0% |
| 16 | HRT FINANCIAL#16 · 54,429 sh | 54,429 | $15.00 | 0.00% | New |
| 17 | FNY Investment Advisers#17 · 3,000 sh | 3,000 | $0.00 | — | 0.0% |
| 18 | Clear Street Group#18 · 1 sh | 1 | $0.00 | 0.00% | New |
Funds that sold out of ENSC in Q2 2026 (2)
Held ENSC at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| VANGUARD FIDUCIARY23,854 sh | 23,854 | $12.9K |
| UBS Group AG8,791 sh | 8,791 | $4.7K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.